Business Context and Reporting Period
This Form 8-K Current Report, dated June 30, 2023, details material transactions executed by Amphastar Pharmaceuticals, Inc. (Amphastar). The filing primarily reports the closing of a significant asset acquisition and the entry into a new credit facility to finance the transaction.
Key Financial Metrics and Transaction Details
Acquisition of BAQSIMI®
- Asset Acquired: BAQSIMI® glucagon nasal powder and related assets from Eli Lilly and Company.
- Upfront Cash Consideration: $500 million paid on the closing date.
- Guaranteed Payment: $125 million due on the first anniversary of the closing.
- Contingent Consideration: Up to $450 million in additional payments based on the achievement of certain milestones.
Debt Financing (Credit Agreement)
- Term Loan: $500 million senior secured term loan, fully funded on the closing date.
- Revolving Credit Facility: $200 million aggregate principal amount (including $15 million letter of credit sublimit and $15 million swingline loan sublimit). No borrowings were outstanding as of the closing date.
- Maturity Date: June 30, 2028.
- Interest Rates:
- Base Rate Loans: Base rate + 1.25% margin (subject to future adjustment based on leverage).
- Term SOFR Loans: Adjusted Term SOFR + 2.25% margin (subject to future adjustment based on leverage).
- Amortization: Term Loan amortizes at 2.5% in Year 1, increasing to 10.0% in Year 5.
Use of Proceeds
Proceeds were utilized to finance the BAQSIMI® acquisition, refinance existing third-party indebtedness, and pay transaction fees and expenses. Remaining proceeds are designated for general corporate purposes.
Material Changes and Agreements
The filing represents a material change in Amphastar's capital structure and asset base. Key agreements executed on June 30, 2023, include:
- Asset Purchase Agreement: Formalized the transfer of BAQSIMI® assets and liabilities from Lilly.
- Manufacturing Services Agreement: Lilly will provide manufacturing, packaging, labeling, and supply services for up to 18 months.
- Transition Services Agreement: Lilly will provide clinical, regulatory, medical affairs, and commercial sales channel support for up to 18 months.
- Covenants: The new Credit Agreement includes financial maintenance covenants requiring a maximum consolidated net leverage ratio and a minimum consolidated interest coverage ratio. It also restricts additional indebtedness, liens, mergers, and dividends.
Outlook, Risks, and Contingencies
- Future Obligations: The company faces a significant cash outflow of $125 million in one year and potential payments up to $450 million contingent on future milestones.
- Debt Service: The company must manage the amortization schedule of the $500 million Term Loan and interest payments on the new debt facilities.
- Operational Transition: Reliance on Lilly for manufacturing and transition services for up to 18 months introduces operational dependency risks during the integration period.
- Default Risks: Events of default include non-payment, covenant breaches, and cross-defaults, which could trigger acceleration of debt obligations and a 2.00% penalty interest rate.
Investor Verification Checklist
- Verify the specific milestones required to trigger the up to $450 million in contingent consideration.
- Review the upcoming Form 10-Q for the full text of the Credit Agreement, Asset Purchase Agreement, and pro forma financial information.
- Assess the company's current consolidated net leverage ratio to determine the applicable interest rate margins and covenant compliance status.
- Monitor the transition timeline for manufacturing and commercial operations to ensure a smooth handover from Lilly within the 18-month window.
- Confirm the details of the "existing third-party indebtedness" that was refinanced to understand the net impact on the balance sheet.